BioWorld MedTech

March 7, 2011

High risk, narrow markets stunting growth for MDx

VIENNA – The bubble of hype surrounding molecular diagnostics (MDx) has burst, leaving Fabian Kiessling, MD, a lone voice still preaching its promise at this radiology congress. (Medical Device Daily) Read More

FDA clears IVD assays from Wako for liver cancer risk

Washington roundup: Medtronic needles CMS into reopening MRI/EP coverage

When a deal value deferred by milestones is still a good deal

Report from Europe: Medtronic launches Achieve mapping catheter in Europe

HIT roundup: TotalQuality certified as EHR technology reporting module

Court Report: Bovie settles patent suit with Medtronic, Salient Surgical

Patent watch: Biolase wins new U.S. patent for treating eye conditions

Med-Tech Notes

Product Briefs

FDA issues a Class I recall of Cook catheter component

Agreements/contracts: ScandiDos Delta4PT to use Varian's RapidArc technology

MDD's Neurology Extra

Today's news in brief

BioWorld

BioWorld briefs for May 21, 2026.

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

News in brief

BioWorld Asia

BioWorld Asia briefs for May 19, 2026

WHO declares Ebola outbreak a public health emergency of international concern

BioWorld

The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...

Nxera Pharma prepares and tests new GPR17 antagonists

BioWorld Science

Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...